Cyteir Therapeutics, Inc. (CYT): Price and Financial Metrics
CYT Price/Volume Stats
| Current price | $2.84 | 52-week high | $2.85 |
| Prev. close | $2.84 | 52-week low | $1.13 |
| Day low | $2.82 | Volume | 11,100 |
| Day high | $2.84 | Avg. volume | 160,123 |
| 50-day MA | $2.76 | Dividend yield | N/A |
| 200-day MA | $2.11 | Market Cap | 102.23M |
CYT Stock Price Chart Interactive Chart >
Cyteir Therapeutics, Inc. (CYT) Company Bio
Cyteir Therapeutics, Inc. operates as a clinical-stage oncology company that develops novel therapeutics based on the biology of DNA repair for the treatment of cancer and synthetic lethality therapeutics for autoimmune diseases. The company engages in manufacturing therapeutics that provide precision targeting of key DNA repair factors to induce diseased cells to self-destruct by DNA damage overload and uses an integrated drug development platform that modulates the imbalance between DNA damage and repair for the therapeutic effect to deliver a pipeline of small molecule therapeutics with a range of potential disease state applications. It provides CYT-0851, an oral small-molecule inhibitor of RAD51-mediated DNA repair. It focuses on providing treatments for a range of hematological malignancies, solid tumors, and chronic autoimmune disorders. The company was incorporated in 2012 and is based in Lexington, Massachusetts.
Latest CYT News From Around the Web
Below are the latest news stories about CYTEIR THERAPEUTICS INC that investors may wish to consider to help them evaluate CYT as an investment opportunity.
Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and DissolutionLEXINGTON, Mass., June 30, 2023--Cyteir Therapeutics, Inc. ("Cyteir" or the "Company") (Nasdaq: CYT) today announced that it is discontinuing all development of CYT-0851, its investigational monocarboxylate transporter inhibitor, and that Cyteir’s Board of Directors has determined, after consideration of potential strategic alternatives, it is in the best interests of its shareholders to dissolve Cyteir, liquidate its assets following an orderly wind down of the Company’s operations, and return |
Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety ProfileLEXINGTON, Mass., June 03, 2023--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a clinical stage oncology company, today presented results from a Phase 1 study with CYT-0851 in combination with capecitabine or gemcitabine in a poster titled "Phase 1 Results of CYT-0851, a Monocarboxylate Transporter (MCT) Inhibitor, in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors" (Abstract: 3099, Poster: 297) at the 2023 American Society of Clinical Oncology (ASCO) annual meeting i |
Cyteir Therapeutics Reports First Quarter 2023 Financial Results and Operational HighlightsLEXINGTON, Mass., May 10, 2023--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a clinical stage oncology company, today reported financial results for the first quarter ended March 31, 2023 and provided an update on recent operational highlights. |
Insiders who bought Cyteir Therapeutics, Inc. (NASDAQ:CYT) last year must be regretting not buying more as market cap hits US$72mCyteir Therapeutics, Inc. ( NASDAQ:CYT ) insiders who purchased shares in the last 12 months were richly rewarded last... |
Cyteir Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Operational HighlightsLEXINGTON, Mass., March 23, 2023--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a clinical stage oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on recent operational highlights. |
CYT Price Returns
| 1-mo | 2.90% |
| 3-mo | N/A |
| 6-mo | 56.91% |
| 1-year | 47.92% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 72.12% |
| 2022 | -85.49% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...